MarketCap
Facebook
X
Telegram
Abiomed Revenue | ABMD
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Abiomed
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.03 B | 848 M | 841 M | 222 M | 174 M | 154 M | 115 M | 85.8 M | 62 M | 46.2 M | 38.2 M | 32.2 M | 85.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 B | 32.2 M | 287 M |
Quarterly Revenue Abiomed
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 266 M | 277 M | - | 261 M | 248 M | 253 M | 261 M | 232 M | 210 M | 165 M | 232 M | 222 M | 205 M | 208 M | 222 M | 201 M | 182 M | 180 M | 201 M | 154 M | 133 M | 132 M | 154 M | 115 M | 103 M | 103 M | 115 M | 85.8 M | 76.4 M | 103 M | 85.8 M | 85.8 M | 76.4 M | 73.4 M | 62 M | 62 M | 51.9 M | 48.8 M | 46.2 M | 46.2 M | 44.3 M | 42.7 M | 38.2 M | 38.2 M | 37.4 M | 38.8 M | 32.2 M | 32.2 M | 29.5 M | 27.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 277 M | 27.4 M | 128 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
64.1 M | - | - | $ 162 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
Myomo
MYO
|
40.9 M | $ 1.01 | 1.0 % | $ 42.3 M | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
InspireMD
NSPR
|
8.98 M | $ 0.65 | -3.68 % | $ 41.8 M |  Israel |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | USA |
 |
Profound Medical Corp.
PROF
|
16.1 M | $ 7.38 | 1.79 % | $ 223 M |  Canada |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Quanterix Corporation
QTRX
|
139 M | $ 3.48 | -1.14 % | $ 148 M | USA |
 |
AVITA Medical
RCEL
|
71.6 M | $ 4.4 | -2.0 % | $ 123 M |  Australia |
 |
AxoGen
AXGN
|
225 M | $ 42.21 | 2.08 % | $ 1.94 B | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Bruker Corporation
BRKR
|
3.44 B | $ 62.84 | -2.33 % | $ 9.54 B | USA |
 |
Smith & Nephew plc
SNN
|
4.56 B | $ 31.56 | -2.46 % | $ 27.4 B |  Britain |
 |
Tactile Systems Technology
TCMD
|
330 M | $ 28.17 | -0.11 % | $ 644 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
TELA Bio
TELA
|
80.3 M | $ 0.73 | 2.83 % | $ 34.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | Canada |
 |
Tandem Diabetes Care
TNDM
|
290 M | $ 19.5 | 2.58 % | $ 1.33 B | USA |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | USA |
 |
Viemed Healthcare
VMD
|
270 M | $ 11.67 | -0.77 % | $ 454 M | USA |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 14.94 | 2.47 % | $ 423 M | USA |
 |
Varex Imaging Corporation
VREX
|
845 M | $ 11.19 | 1.08 % | $ 463 M | USA |
 |
Avanos Medical
AVNS
|
701 M | $ 24.99 | - | $ 1.16 B | USA |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
Inogen
INGN
|
349 M | $ 6.45 | 0.47 % | $ 172 M | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.36 | 3.08 % | $ 22.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
52.7 M | $ 0.82 | -1.39 % | $ 13.9 M | USA |
 |
Integer Holdings Corporation
ITGR
|
1.85 B | $ 121.21 | 20.18 % | $ 4.21 B | USA |
 |
Beyond Air
XAIR
|
7.68 M | $ 5.28 | -2.68 % | $ 43.8 B | USA |
 |
Xtant Medical Holdings
XTNT
|
134 M | $ 0.43 | -0.6 % | $ 60 M | USA |
 |
LivaNova PLC
LIVN
|
1.39 B | $ 80.14 | -1.12 % | $ 4.37 B | Britain |
 |
NanoVibronix
NAOV
|
2.55 M | - | - | $ 1.08 M | USA |